» Articles » PMID: 34089099

Clinical Features and Outcomes of 76 Patients with COVID-19-related Multi-system Inflammatory Syndrome in Children

Abstract

Objectives: Multi-system inflammatory syndrome in children (MIS-C) is a less understood and a rare complication of coronavirus disease-2019 (COVID-19). Given the scarce data regarding this novel disease, we aimed to describe the clinical features and outcomes of our patients with MIS-C and to evaluate the associated factors for the pediatric intensive care unit (PICU) admission.

Methods: The MIS-C patients under 18 years old diagnosed and treated in three referral centers between July 2020 and March 2021 were included. Data of the patients were retrospectively obtained from their medical records.

Results: Overall, 76 subjects (24 females) with a mean age of 8.17 ± 4.42 years were enrolled. Twenty-seven (35.5%) patients were admitted to the PICUs. The two most common systemic involvement patterns were cardiac and gastrointestinal. There was only one lethal outcome in a patient with underlying acute lymphoblastic leukemia. Those with higher procalcitonin levels at admission were found to stay longer in the hospital (r = 0.254, p = 0.027). The risk of PICU admission increased with age (aOR: 1.277; 95% CI: 1.089-1.498; p = 0.003) and with decreased initial serum albumin levels (aOR: 0.105; 95% CI: 0.029-0.378; p = 0.001).

Conclusion: Although there is a wide clinical variability among the patients with MIS-C, we suggest that those with older age and lower initial serum albumin levels merit close monitoring due to their higher risk for PICU admission. Key Points • Although there is a wide variability regarding the management process among clinicians, MIS-C is a rare, severe, less understood complication of COVID-19 that may cause rapid clinical deterioration in the patients. • Clinicians should be aware of this condition in children with persistent fever and a family history of COVID-19. • Older age and low serum albumin levels are the independent predictors for the pediatric intensive care unit admission among MIS-C patients.

Citing Articles

Cardiogenic Shock Risk Score at Diagnosis of Multisystem Inflammatory Syndrome in Children: A Multicenter Study.

Bichali S, Ouldali N, Genin M, Toubiana J, Belot A, Levy C Pediatr Cardiol. 2025; .

PMID: 40069379 DOI: 10.1007/s00246-025-03823-7.


Plasma IL-17A is increased in patients with critical MIS-C and associated to in-hospital mortality.

de Farias E, do Nascimento L, Pavao Junior M, Pavao D, Pinheiro A, Pinheiro A Front Immunol. 2025; 15:1485009.

PMID: 39931580 PMC: 11807959. DOI: 10.3389/fimmu.2024.1485009.


COVID-19 infection in children with blood cancer: A systematic review.

Alhumaid S, Al Noaim K, Almuslim A, Turkistani J, Alqurini Z, Alshakhs A Ann Hematol. 2024; .

PMID: 39496811 DOI: 10.1007/s00277-024-06057-4.


In-hospital unfavorable outcomes of MIS-C during 2020-2022: a systematic review.

Alvarado-Gamarra G, Alcala-Marcos K, Balmaceda-Nieto P, Visconti-Lopez F, Torres-Balarezo P, Moran-Marinos C Eur J Pediatr. 2024; 183(12):5071-5084.

PMID: 39349752 DOI: 10.1007/s00431-024-05787-x.


Clinical and Laboratory Parameters Associated with PICU Admission in Children with Multisystem Inflammatory Syndrome Associated with COVID-19 (MIS-C).

Dourdouna M, Mpourazani E, Tatsi E, Tsirogianni C, Barbaressou C, Dessypris N J Pers Med. 2024; 14(9).

PMID: 39338265 PMC: 11432765. DOI: 10.3390/jpm14091011.


References
1.
Netea M, Giamarellos-Bourboulis E, Dominguez-Andres J, Curtis N, van Crevel R, van de Veerdonk F . Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell. 2020; 181(5):969-977. PMC: 7196902. DOI: 10.1016/j.cell.2020.04.042. View

2.
Alharbi M, Kazzaz Y, Hameed T, Alqanatish J, Alkhalaf H, Alsadoon A . SARS-CoV-2 infection in children, clinical characteristics, diagnostic findings and therapeutic interventions at a tertiary care center in Riyadh, Saudi Arabia. J Infect Public Health. 2021; 14(4):446-453. PMC: 7833958. DOI: 10.1016/j.jiph.2020.12.034. View

3.
Wood L, Tulloh R . Kawasaki disease in children. Heart. 2008; 95(10):787-92. DOI: 10.1136/hrt.2008.143669. View

4.
Basar E, Sonmez H, Oncel S, Yetimakman A, Babaoglu K . Multisystemic inflammatory syndrome in children associated with COVID-19: a single center experience in Turkey. Turk Arch Pediatr. 2021; 56(3):192-199. PMC: 8152650. DOI: 10.5152/TurkArchPediatr.2021.21018. View

5.
McCrindle B, Li J, Minich L, Colan S, Atz A, Takahashi M . Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007; 116(2):174-9. DOI: 10.1161/CIRCULATIONAHA.107.690875. View